BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ritzmann F, Jungnickel C, Vella G, Kamyschnikow A, Herr C, Li D, Menger MM, Angenendt A, Hoth M, Lis A, Bals R, Beisswenger C. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer. Sci Rep 2019;9:10353. [PMID: 31316109 DOI: 10.1038/s41598-019-46759-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Nies JF, Panzer U. IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology. Front Immunol 2020;11:341. [PMID: 32174926 DOI: 10.3389/fimmu.2020.00341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
2 Sprott RF, Ritzmann F, Langer F, Yao Y, Herr C, Kohl Y, Tschernig T, Bals R, Beisswenger C. Flagellin shifts 3D bronchospheres towards mucus hyperproduction. Respir Res 2020;21:222. [PMID: 32847538 DOI: 10.1186/s12931-020-01486-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Narayanapillai SC, Han YH, Song JM, Kebede ME, Upadhyaya P, Kassie F. Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis. Carcinogenesis 2020;41:1518-28. [PMID: 32602900 DOI: 10.1093/carcin/bgaa059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
4 Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun 2020;11:5439. [PMID: 33116132 DOI: 10.1038/s41467-020-19288-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
5 Ritzmann F, Lunding LP, Bals R, Wegmann M, Beisswenger C. IL-17 Cytokines and Chronic Lung Diseases. Cells 2022;11:2132. [DOI: 10.3390/cells11142132] [Reference Citation Analysis]
6 Steck P, Ritzmann F, Honecker A, Vella G, Herr C, Gaupp R, Bischoff M, Speer T, Tschernig T, Bals R, Beisswenger C. Interleukin 17 Receptor E (IL-17RE) and IL-17C Mediate the Recruitment of Neutrophils during Acute Streptococcus pneumoniae Pneumonia. Infect Immun 2019;87:e00329-19. [PMID: 31481409 DOI: 10.1128/IAI.00329-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ritzmann F, Borchardt K, Vella G, Chitirala P, Angenendt A, Herr C, Menger MD, Hoth M, Lis A, Bohle RM, Bals R, Beisswenger C. Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD. Am J Physiol Lung Cell Mol Physiol 2021;320:L958-68. [PMID: 33759577 DOI: 10.1152/ajplung.00121.2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Pätzold L, Stark A, Ritzmann F, Meier C, Tschernig T, Reichrath J, Bals R, Bischoff M, Beisswenger C. IL-17C and IL-17RE Promote Wound Closure in a Staphylococcus aureus-Based Murine Wound Infection Model. Microorganisms 2021;9:1821. [PMID: 34576717 DOI: 10.3390/microorganisms9091821] [Reference Citation Analysis]
9 Lingling Z, Jiewei L, Li W, Danli Y, Jie Z, Wen L, Dan P, Lei P, Qinghua Z. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology - Research and Practice 2020;216:152852. [DOI: 10.1016/j.prp.2020.152852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Kim TO, Park KJ, Cho YN, Jin HM, Jo YG, Kim HS, Ju JK, Shin HJ, Kho BG, Kee SJ, Park YW. Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome. Thorax 2022:thoraxjnl-2021-217724. [PMID: 35086913 DOI: 10.1136/thoraxjnl-2021-217724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li S, Na R, Li X, Zhang Y, Zheng T. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer. Biochim Biophys Acta Rev Cancer 2022;1877:188758. [PMID: 35809762 DOI: 10.1016/j.bbcan.2022.188758] [Reference Citation Analysis]
12 Vella G, Ritzmann F, Wolf L, Kamyschnikov A, Stodden H, Herr C, Slevogt H, Bals R, Beisswenger C. IL-17C contributes to NTHi-induced inflammation and lung damage in experimental COPD and is present in sputum during acute exacerbations. PLoS One 2021;16:e0243484. [PMID: 33411748 DOI: 10.1371/journal.pone.0243484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Vella G, Lunding L, Ritzmann F, Honecker A, Herr C, Wegmann M, Bals R, Beisswenger C. The IL-17 receptor IL-17RE mediates polyIC-induced exacerbation of experimental allergic asthma. Respir Res 2020;21:176. [PMID: 32641167 DOI: 10.1186/s12931-020-01434-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Laba S, Mallett G, Amarnath S. The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. Semin Cancer Biol 2021:S1044-579X(21)00153-X. [PMID: 34048897 DOI: 10.1016/j.semcancer.2021.05.022] [Reference Citation Analysis]
15 Ritzmann F, Beisswenger C. Preclinical studies and the function of IL-17 cytokines in COPD. Ann Anat 2021;237:151729. [PMID: 33798693 DOI: 10.1016/j.aanat.2021.151729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Dias Carvalho P, Machado AL, Martins F, Seruca R, Velho S. Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Cancers (Basel) 2019;11:E2010. [PMID: 31847096 DOI: 10.3390/cancers11122010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
17 Liu W, Xia L, Xia Z, Chen L. Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients. Genes 2022;13:88. [DOI: 10.3390/genes13010088] [Reference Citation Analysis]
18 Li Q, Ngo PT, Egilmez NK. Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy. Cancer Immunol Immunother 2021;70:1789-96. [PMID: 33245376 DOI: 10.1007/s00262-020-02795-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]